Resonance Health Ltd has released a press release.
New Pulmonary Embolism AI Solution Developed
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Resonance Health
- Execution of Licence Agreement
- Resonance Health Files New Provisional Patent
- Market Update
- Controlled Placement Facility
- Licencee & Royalty Agreement with 3DR Laboratories
Later from Resonance Health
- HepaFat-AI gains US FDA clearance
- HepaFat-AI Incorporated into Blackford Analysis
- HepaFat-AI Receives TGA Approval
- HepaFat-AI receives CE Marking
- Appendix 4C - quarterly
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health